A BILL 
To establish the ‘‘Biomedical Innovation Fund’’, and for 
other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘National Biomedical 
4
Research Act’’. 
5
SEC. 2. DEFINITIONS. 
6
In this Act: 
7
(1) 
DISCRETIONARY
APPROPRIATIONS.—The 
8
term ‘‘discretionary appropriations’’ has the mean-
9
03:18 Jul 10, 2021
H4124
2 
•HR 4124 IH
ing given such term in section 250 of the Balanced 
1
Budget and Emergency Deficit Control Act of 1985 
2
(2 U.S.C. 900). 
3
(2) FUND.—The term ‘‘Fund’’ means the Bio-
4
medical Innovation Fund established under section 
5
3(a). 
6
(3) MINIMUM AMOUNT.—The term ‘‘minimum 
7
amount’’, with respect to the applicable entity and 
8
for an applicable fiscal year— 
9
(A) means the amount equal to the great-
10
est amount of discretionary appropriations ap-
11
propriated to such entity for a fiscal year dur-
12
ing the period beginning with fiscal year 2022 
13
and ending with the fiscal year before the appli-
14
cable fiscal year; and 
15
(B) does not include— 
16
(i) any reduction in an appropriation 
17
under a sequestration order issued under 
18
the Balanced Budget and Emergency Def-
19
icit Control Act of 1985 (2 U.S.C. 900 et 
20
seq.); 
21
(ii) amounts collected by the Secretary 
22
of Health and Human Services under sub-
23
chapter C of chapter VII of the Federal 
24
03:18 Jul 10, 2021
H4124
3 
•HR 4124 IH
Food, Drug, and Cosmetic Act (21 U.S.C. 
1
379f et seq.); 
2
(iii) amounts distributed under section 
3
3(c)(2); or 
4
(iv) amounts appropriated under a 
5
supplemental or emergency appropriation 
6
Act. 
7
SEC. 3. BIOMEDICAL INNOVATION FUND. 
8
(a) ESTABLISHMENT.—There is established in the 
9
Treasury of the United States a fund to be known as the 
10
‘‘Biomedical Innovation Fund’’, to be administered by the 
11
Secretary of the Treasury, consisting of— 
12
(1) the amounts transferred to the Fund under 
13
subsection (b); and 
14
(2) any interest earned on the investment of 
15
such amounts under subsection (d). 
16
(b) COMMITMENT TO BIOMEDICAL INNOVATION.— 
17
Not later than September 1, 2022, and every year there-
18
after through 2031, the Secretary of the Treasury shall 
19
transfer $10,000,000,000 from the general fund of the 
20
Treasury into the Fund. 
21
(c) DISTRIBUTION OF AMOUNTS.— 
22
(1) 
CALCULATION
OF
ANNUAL
FUND 
23
AMOUNT.—For fiscal year 2022 and each fiscal year 
24
thereafter, not later than 15 days after the latter of 
25
03:18 Jul 10, 2021
H4124
4 
•HR 4124 IH
the date of enactment of an appropriation Act mak-
1
ing full fiscal year appropriations for such fiscal year 
2
to the entity described in paragraph (2)(A) and the 
3
date of enactment of an appropriation Act making 
4
full fiscal year appropriations for such fiscal year to 
5
the entity described in paragraph (2)(B), the Sec-
6
retary of the Treasury shall calculate the total 
7
amount in the Fund that is available to be distrib-
8
uted for such fiscal year in accordance with para-
9
graph (2). 
10
(2) DISTRIBUTION
OF
AMOUNTS
IN
THE 
11
FUND.—Subject to the other provisions of this sec-
12
tion, not later than 30 days after a calculation is 
13
made under paragraph (1) for a fiscal year, the Sec-
14
retary of the Treasury shall distribute the amount 
15
available to be distributed for such fiscal year to 
16
each of the following entities: 
17
(A) The National Institutes of Health. 
18
(B) The Food and Drug Administration. 
19
(3) RATIO.—The amount that the Secretary of 
20
the Treasury distributes to an entity described in 
21
subparagraph (A) or (B) of paragraph (2) during a 
22
fiscal year shall bear the same relation to the total 
23
amount calculated under paragraph (1) for such fis-
24
cal year as the amount of discretionary appropria-
25
03:18 Jul 10, 2021
H4124
5 
•HR 4124 IH
tions appropriated to such entity for such fiscal year 
1
bears to the total amount of discretionary appropria-
2
tions appropriated to the entities described in sub-
3
paragraphs (A) and (B) of paragraph (2) for such 
4
fiscal year. 
5
(4) REQUIREMENTS FOR DISTRIBUTION.— 
6
(A) IN GENERAL.—The Secretary of the 
7
Treasury shall distribute amounts in the Fund 
8
during a fiscal year in accordance with para-
9
graph (2) only if— 
10
(i) the discretionary appropriations 
11
for the entity described in paragraph 
12
(2)(A) is greater than the applicable min-
13
imum amount for such entity for such fis-
14
cal year; and 
15
(ii) the discretionary appropriations 
16
for the entity described in paragraph 
17
(2)(B) is greater than the applicable min-
18
imum amount for such entity for such fis-
19
cal year. 
20
(B) SUBSEQUENT
LAW
IMPACTING
DIS-
21
TRIBUTION.— 
22
(i) BELOW MINIMUM AMOUNT.—If a 
23
law is enacted or becomes effective after 
24
amounts are appropriated to each entity 
25
03:18 Jul 10, 2021
H4124
6 
•HR 4124 IH
described in subparagraph (A) or (B) of 
1
paragraph (2) for a fiscal year and such 
2
law decreases the amount appropriated to 
3
either such entity for such fiscal year from 
4
an amount that is greater than the appli-
5
cable minimum amount to an amount that 
6
is less than or equal to such minimum 
7
amount, any amounts that were distributed 
8
by the Secretary of the Treasury under 
9
paragraph (2) shall remain so distributed 
10
for such fiscal year. 
11
(ii) ABOVE MINIMUM AMOUNT.—If a 
12
law is enacted or becomes effective after 
13
amounts are appropriated for a fiscal year 
14
to each entity described in subparagraph 
15
(A) or (B) of paragraph (2) and such law 
16
increases the amount appropriated to ei-
17
ther such entity for such fiscal year from 
18
an amount that is less than or equal to the 
19
minimum amount to an amount that is 
20
greater than such minimum amount, and 
21
all other conditions for distribution under 
22
this paragraph are met for the fiscal year, 
23
the amounts in the Fund shall be distrib-
24
03:18 Jul 10, 2021
H4124
7 
•HR 4124 IH
uted by the Secretary of the Treasury 
1
under paragraph (2) for such fiscal year. 
2
(C) FAILURE TO MEET REQUIREMENTS.— 
3
If the requirements under subparagraph (A) 
4
are not met during a fiscal year, amounts in the 
5
Fund shall— 
6
(i) not be distributed under paragraph 
7
(2); and 
8
(ii) remain in the Fund, earning inter-
9
est in accordance with subsection (d), until 
10
such requirements, or the conditions under 
11
subsection (f), are met during a fiscal year. 
12
(5) ALLOCATIONS.— 
13
(A) IN GENERAL.—If amounts are distrib-
14
uted under paragraph (2) during a fiscal year, 
15
of the amounts so distributed— 
16
(i) 20 percent shall become available 
17
for obligation during the fiscal year during 
18
which the distribution is made; 
19
(ii) 20 percent shall become available 
20
for obligation during the first fiscal year 
21
after the fiscal year during which the dis-
22
tribution is made; 
23
(iii) 20 percent shall become available 
24
for obligation during the second fiscal year 
25
03:18 Jul 10, 2021
H4124
8 
•HR 4124 IH
after the fiscal year during which the dis-
1
tribution is made; 
2
(iv) 20 percent shall become available 
3
for obligation during the third fiscal year 
4
after the fiscal year during which the dis-
5
tribution is made; and 
6
(v) 20 percent shall become available 
7
for obligation during the fourth fiscal year 
8
after the fiscal year during which the dis-
9
tribution is made. 
10
(B) AVAILABILITY
OF
AMOUNTS.—Any 
11
amounts distributed under paragraph (2) shall 
12
remain available until expended. 
13
(6) AUTHORIZED USES.—Amounts distributed 
14
under paragraph (2) from the Fund shall be used to 
15
support— 
16
(A) basic research on the underlying basis 
17
for disease to better address disease prevention, 
18
diagnosis, and treatment; 
19
(B) research that fosters disruptive innova-
20
tion, such as— 
21
(i) research on diseases or conditions 
22
for which treatments exist but are inad-
23
equate, including chronic and acute pain; 
24
03:18 Jul 10, 2021
H4124
9 
•HR 4124 IH
(ii) research on diseases or conditions 
1
for which there are unmet medical needs; 
2
(iii) research on diseases or conditions 
3
for which treatments exist but the side ef-
4
fect profiles of such treatments limit thera-
5
peutic potential; 
6
(iv) research on new approaches to 
7
treatment of diseases using drugs, devices, 
8
or therapies that, at the time of distribu-
9
tion under paragraph (2), are not used or 
10
are underused; or 
11
(v) research conducted by experienced 
12
investigators with a history of productive 
13
and innovative research, such that funding 
14
provides long-term stability for such re-
15
search and allows such investigators to 
16
take greater risks, be more adventurous in 
17
their lines of inquiry, or take the time to 
18
develop groundbreaking techniques; 
19
(C) research related to diseases that 
20
disproportionally account for Federal health 
21
care spending, including spending under the 
22
Medicare program under title XVIII of the So-
23
cial Security Act (42 U.S.C. 1395 et seq.), the 
24
Medicaid program under title XIX of the Social 
25
03:18 Jul 10, 2021
H4124
10 
•HR 4124 IH
Security Act (42 U.S.C. 1396 et seq.), the 
1
State Children’s Health Insurance Program 
2
under title XXI of the Social Security Act (42 
3
U.S.C. 1397aa et seq.), the TRICARE program 
4
under chapter 55 of title 10, United States 
5
Code, and hospital care and medical services 
6
furnished by the Department of Veterans Af-
7
fairs under chapters 17 and 18 of title 38, 
8
United States Code, such as research relating 
9
to— 
10
(i) diseases that disproportionally im-
11
pact older individuals; 
12
(ii) degenerative diseases; or 
13
(iii) chronic conditions; 
14
(D) early career scientists, such as 
15
through— 
16
(i) awarding research project grants 
17
that support discrete, specified, and cir-
18
cumscribed projects to be performed by the 
19
investigator in an area representing the 
20
specific interests and competencies of such 
21
investigator, to investigators— 
22
(I) who are within 10 years of 
23
completing a terminal research de-
24
gree; or 
25
03:18 Jul 10, 2021
H4124
11 
•HR 4124 IH
(II) who are within 10 years of 
1
completing a medical residency; 
2
(ii) awarding grants that support ca-
3
reer development experiences that lead to 
4
earlier research independence; and 
5
(iii) awarding grants that support in-
6
novative training programs that, in addi-
7
tion to scientific training, provide addi-
8
tional training to enhance employment op-
9
portunities, including training in manage-
10
ment and business, to— 
11
(I) graduate students; 
12
(II) post-doctoral fellows; 
13
(III) individuals within 10 years 
14
of completing a terminal research de-
15
gree; or 
16
(IV) individuals within 10 years 
17
of completing a medical residency; 
18
(E) research efforts that increase the po-
19
tential for breakthrough discoveries across a di-
20
verse set of investigators, research groups, and 
21
institutions, which may include supporting— 
22
(i) investigators that are members of 
23
traditionally underrepresented racial and 
24
ethnic groups; 
25
03:18 Jul 10, 2021
H4124
12 
•HR 4124 IH
(ii) research groups that are diverse 
1
in size; or 
2
(iii) institutions that increase the geo-
3
graphic diversity of funding provided by 
4
the National Institutes of Health; 
5
(F) the development, review, and post-mar-
6
ket surveillance of medical products, as deter-
7
mined by the Secretary of Health and Human 
8
Services; and 
9
(G) research to carry out the goals of the 
10
strategy and implementation plan for advancing 
11
science to promote public health and advance 
12
innovation in regulatory decision making devel-
13
oped under section 1124 of the Food and Drug 
14
Administration Safety and Innovation Act (21 
15
U.S.C. 393 note), and other such research ac-
16
tivities to improve the predictability, consist-
17
ency, and efficiency of science-based decision 
18
making concerning medical products, including 
19
facilitating the timely introduction of new tech-
20
nologies and methodologies in a safe and effec-
21
tive manner as determined by the Secretary of 
22
Health and Human Services. 
23
(7) INTERAGENCY TRANSFERS.—Amounts dis-
24
tributed from the Fund under paragraph (2) shall 
25
03:18 Jul 10, 2021
H4124
13 
•HR 4124 IH
be available through interagency transfer to support 
1
research conducted jointly by the National Institutes 
2
of Health or the Food and Dug Administration and 
3
other Federal agencies. 
4
(d) INVESTMENT OF FUND BALANCES.— 
5
(1) IN GENERAL.—Amounts in the Fund shall 
6
be invested in interest-bearing obligations of the 
7
United States in the form of special-issue securities, 
8
paying interest to the Fund at rates applicable to 
9
such securities, and such amounts shall be redeem-
10
able by the Secretary of the Treasury, for purposes 
11
of distribution under subsection (c)(2). 
12
(2) DISTRIBUTED
AMOUNTS.—Any amounts 
13
that have been distributed during a fiscal year under 
14
subsection (c)(2) shall not be considered amounts in 
15
the Fund for the purpose of this subsection. 
16
(e) PROHIBITION.—Amounts in the Fund may not be 
17
made available for any use other than a use described in 
18
subsection (c)(6). 
19
(f) TRANSFER TO REDUCE THE DEFICIT.— 
20
(1) IN GENERAL.—Subject to paragraph (2), if 
21
amounts in the Fund are not distributed by the Sec-
22
retary of the Treasury under subsection (c)(2) for 
23
any 3 consecutive fiscal years, the Secretary of the 
24
Treasury shall transfer all amounts in the Fund to 
25
03:18 Jul 10, 2021
H4124
14 
•HR 4124 IH
the general fund of the Treasury for purposes of re-
1
ducing the Federal deficit. 
2
(2) YEAR OF DISTRIBUTION.—For purposes of 
3
paragraph (1), 3 fiscal years shall not be deemed to 
4
be consecutive if during any of such years the Sec-
5
retary of the Treasury has transferred all amounts 
6
in the Fund into the general fund of the Treasury 
7
in accordance with such paragraph. 
8
(g) REPORTS.— 
9
(1) SECRETARY REPORTS.— 
10
(A) IN GENERAL.—Not later than Novem-
11
ber 30, 2023, and every year thereafter through 
12
2032 the Secretary of the Treasury shall sub-
13
mit to the Committee on Appropriations of the 
14
Senate, the Committee on Appropriations of the 
15
House of Representatives, and the authorizing 
16
committees a report on the operation of the 
17
Fund during the fiscal year. 
18
(B) CONTENTS.—Each report shall in-
19
clude, for the fiscal year covered by the report, 
20
each of the following: 
21
(i) A statement of the amounts, and 
22
the source of such amounts, transferred to, 
23
credited to, and deposited into the Fund. 
24
03:18 Jul 10, 2021
H4124
15 
•HR 4124 IH
(ii) A description of any amounts dis-
1
tributed under subsection (c)(2) during the 
2
fiscal year. 
3
(iii) A statement of the balance re-
4
maining in the Fund at the end of the fis-
5
cal year. 
6
(iv) A statement of the amounts in-
7
vested in interest-bearing obligations of the 
8
United States, and the interest earned on 
9
such investments. 
10
(2) AGENCY REPORTS.— 
11
(A) ANNUAL REPORTING.—For each fiscal 
12
year in which amounts are available for obliga-
13
tion under subsection (c)(5), the Director of the 
14
National Institutes of Health and the Commis-
15
sioner of Food and Drugs shall report on the 
16
use of such amounts in the annual budget sub-
17
mission for such fiscal year of the National In-
18
stitutes of Health and the Food and Drug Ad-
19
ministration, respectively. 
20
(B) NIH REPORTS.—Section 403(a) of the 
21
Public Health Service Act (42 U.S.C. 283(a)) is 
22
amended by adding at the end the following: 
23
‘‘(7) A summary of the use of funds distributed 
24
under section 3(c)(2)(A) of the National Biomedical 
25
03:18 Jul 10, 2021
H4124
16 
•HR 4124 IH
Research Act to the National Institutes of Health 
1
from the Biomedical Innovation Fund, established 
2
under section 3(a) of such Act, including the 
3
amounts allocated to each national research institute 
4
and national center, the projects funded by such 
5
amounts, the accomplishments that have resulted 
6
from such amounts, and the goals for future use of 
7
such amounts.’’. 
8
(C) FDA REPORTS.—For each 3-year pe-
9
riod beginning on the date of enactment of this 
10
Act, if amounts are distributed under sub-
11
section (c)(2)(B) to the Food and Drug Admin-
12
istration for any fiscal year during such 3-year 
13
period, the Commissioner of Food and Drugs 
14
shall submit, to the Committee on Health, Edu-
15
cation, Labor, and Pensions of the Senate and 
16
the Committee on Energy and Commerce of the 
17
House of Representatives, a report that de-
18
scribes the allocation of such amounts within 
19
the Food and Drug Administration, the projects 
20
funded by such amounts, the accomplishments 
21
that have resulted from such amounts, and the 
22
goals for future use of such amounts. 
23
03:18 Jul 10, 2021
H4124
17 
•HR 4124 IH
SEC. 4. BUDGETARY PROVISIONS. 
1
(a) DISCRETIONARY SPENDING LIMITS.—The Office 
2
of Management and Budget shall not include amounts dis-
3
tributed under section 3(c)(2) during a fiscal year in de-
4
termining whether there has been a breach of the discre-
5
tionary spending limits under the Balanced Budget and 
6
Emergency Deficit Control Act of 1985 (2 U.S.C. 900 et 
7
seq.) during the fiscal year. 
8
(b) BUDGET ENFORCEMENT.—If a bill or joint reso-
9
lution, or amendment thereto or conference report there-
10
on, if enacted, would cause amounts to be distributed 
11
under section 3(c)(2), the Chairperson of the Committee 
12
on the Budget of the House of Representatives and Chair-
13
person of the Committee on the Budget of the Senate shall 
14
not include the budgetary effects of such distribution for 
15
purposes of enforcement of budgetary allocations, aggre-
16
gates, levels, and limits in the House of Representatives 
17
and the Senate. 
18
SEC. 5. OFFSETS. 
19
It is the sense of the House of Representatives that 
20
the amounts transferred under section 3(b) should be off-
21
set completely. 
22
Æ 
03:18 Jul 10, 2021
H4124
